Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
CANF 
Can Fite Biopharma Ltd ADR (CANF)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/16/2025: CANF (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
2 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $7.75
1 Year Target Price $7.75
| 2 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -44.59% | Avg. Invested days 25 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  2.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 09/16/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 14.24M USD | Price to earnings Ratio - | 1Y Target Price 7.75 |
Price to earnings Ratio - | 1Y Target Price 7.75 | ||
Volume (30-day avg) 2 | Beta 0.09 | 52 Weeks Range 0.63 - 3.12 | Updated Date 09/15/2025 |
52 Weeks Range 0.63 - 3.12 | Updated Date 09/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date 2025-08-28 | When Before Market | Estimate -0.12 | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -2424.75% |
Management Effectiveness
Return on Assets (TTM) -81.86% | Return on Equity (TTM) -264.12% |
Valuation
Trailing PE - | Forward PE 2.97 | Enterprise Value 7870939 | Price to Sales(TTM) 25.43 |
Enterprise Value 7870939 | Price to Sales(TTM) 25.43 | ||
Enterprise Value to Revenue 14.06 | Enterprise Value to EBITDA 0.1 | Shares Outstanding 15772900 | Shares Floating 3966812282 |
Shares Outstanding 15772900 | Shares Floating 3966812282 | ||
Percent Insiders - | Percent Institutions 5.89 |
Upturn AI SWOT
Can Fite Biopharma Ltd ADR
Company Overview
History and Background
Can-Fite BioPharma Ltd. was founded in 2000 and is an Israeli biopharmaceutical company focused on developing and commercializing orally available drugs for the treatment of liver, inflammatory and metabolic diseases. It is listed on the NYSE American under the symbol CANF.
Core Business Areas
- Liver Diseases: Development of Piclidenoson for the treatment of liver diseases, including Non-Alcoholic Steatohepatitis (NASH) and hepatocellular carcinoma (HCC).
- Inflammatory Diseases: Development of Piclidenoson for the treatment of inflammatory diseases, such as psoriasis and rheumatoid arthritis.
- Metabolic Diseases: Research and development in the area of metabolic diseases.
Leadership and Structure
Can-Fite is led by a management team with experience in drug development and commercialization. The company has a board of directors responsible for corporate governance.
Top Products and Market Share
Key Offerings
- Piclidenoson: An A3 adenosine receptor agonist (A3AR) being developed for the treatment of NASH, HCC, psoriasis, and rheumatoid arthritis. Currently in clinical trials. Market share is currently 0%, as the product is not yet approved. Competitors in the NASH market include Madrigal Pharmaceuticals (Resmetirom) and Viking Therapeutics (VK2809), as well as various other pharmaceutical companies developing NASH treatments.
Market Dynamics
Industry Overview
The biopharmaceutical industry is characterized by high research and development costs, long development timelines, and stringent regulatory requirements. The liver disease and inflammatory disease markets are large and growing, driven by increasing prevalence and unmet medical needs.
Positioning
Can-Fite is positioned as a developer of innovative, orally available drugs targeting the A3AR. Its competitive advantage lies in its proprietary technology and focus on unmet medical needs.
Total Addressable Market (TAM)
The total addressable market for NASH alone is estimated to be billions of dollars. Can-Fite's positioning depends on successful clinical trials and regulatory approval.
Upturn SWOT Analysis
Strengths
- Proprietary A3AR technology
- Orally available drug candidates
- Focus on unmet medical needs
- Experienced management team
Weaknesses
- Limited financial resources
- Dependence on clinical trial success
- Lack of commercial infrastructure
- Concentrated product pipeline
Opportunities
- Positive clinical trial results
- Partnerships with larger pharmaceutical companies
- Expansion into new indications
- Regulatory approval of Piclidenoson
Threats
- Clinical trial failures
- Competition from other pharmaceutical companies
- Regulatory hurdles
- Changes in reimbursement policies
Competitors and Market Share
Key Competitors
- MRNA
- GILD
- AMGN
- BMY
Competitive Landscape
Can-Fite faces significant competition from larger pharmaceutical companies with greater resources and established market presence. Its competitive advantage lies in its novel A3AR technology and focus on specific indications.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is characterized by increases in research and development spending as the company progresses its clinical trials.
Future Projections: Future growth is dependent on the successful completion of clinical trials and regulatory approval. Analyst estimates will vary widely based on anticipated success rates.
Recent Initiatives: Recent initiatives include enrolling patients in ongoing clinical trials for Piclidenoson and seeking partnerships for commercialization.
Summary
Can-Fite Biopharma is a clinical-stage company with potential upside linked to successful clinical trials, particularly for Piclidenoson. It has a focused therapeutic area, but faces significant financial and competitive hurdles due to its limited resources and reliance on trial outcomes. Positive clinical results and strategic partnerships are crucial for the company's success, while clinical trial failures would negatively impact its prospects.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- SEC filings
- Analyst reports
- Industry publications
Disclaimers:
This analysis is based on publicly available information and should not be considered financial advice. Investment decisions should be made after consulting with a qualified financial advisor.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Can Fite Biopharma Ltd ADR
Exchange NYSE MKT | Headquaters - | ||
IPO Launch date 2012-11-06 | CEO and Chief Financial & Operating Officer Mr. Motti Farbstein | ||
Sector Healthcare | Industry Biotechnology | Full time employees 5 | Website https://www.canfite.com |
Full time employees 5 | Website https://www.canfite.com | ||
Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction in Israel. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis. It develops Namodenoson that is in Phase III clinical trial for the treatment of liver cancer; and Phase IIa for the treatment of pancreatic cancer; as well as in Phase IIb trial for the treatment of metabolic associated steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. It has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. The company was incorporated in 1994 and is headquartered in Ramat Gan, Israel.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.